Revolve Wealth Partners LLC Buys 4,737 Shares of Abbott Laboratories $ABT

Revolve Wealth Partners LLC boosted its position in shares of Abbott Laboratories (NYSE:ABT) by 124.6% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,539 shares of the healthcare product maker’s stock after buying an additional 4,737 shares during the quarter. Revolve Wealth Partners LLC’s holdings in Abbott Laboratories were worth $775,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. MidAtlantic Capital Management Inc. bought a new stake in shares of Abbott Laboratories in the 4th quarter worth about $25,000. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories during the 4th quarter valued at about $25,000. Purpose Unlimited Inc. purchased a new stake in Abbott Laboratories in the 4th quarter worth about $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories in the fourth quarter worth about $26,000. Finally, Abound Financial LLC bought a new stake in Abbott Laboratories in the fourth quarter worth about $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on ABT. Stifel Nicolaus cut their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Oppenheimer dropped their price objective on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Wells Fargo & Company upped their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Argus reduced their target price on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Finally, Daiwa Securities Group lowered shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price for the company. in a research note on Wednesday, April 22nd. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average target price of $118.17.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $109.70 on Wednesday. The company has a 50 day moving average price of $96.38 and a 200-day moving average price of $99.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The company has a market capitalization of $189.82 billion, a PE ratio of 35.50, a P/E/G ratio of 2.10 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.Abbott Laboratories’s revenue was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.